Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
Article Date
June 24, 2025
This article is featured on another website.
Go to article
March 10, 2026
Base to Base Biotech podcast with Sean A. MacDonald, CEO at Kainova Therapeutics – GPCRs and beating neurodegenerative diseases
March 10, 2026
Base to Base Biotech podcast with Sean A. MacDonald, CEO at Kainova Therapeutics – GPCRs and beating neurodegenerative diseases
January 26, 2026
Maximizing Global Study Value: Clinical Trial Landscapes in South Korea and Japan
Clinical trial globalization continues to be a major trend for industry-sponsored clinical trials. More recently,…
January 26, 2026
Maximizing Global Study Value: Clinical Trial Landscapes in South Korea and Japan
Clinical trial globalization continues to be a major trend for industry-sponsored clinical trials. More recently,…